Dosage forms and therapeutic uses of L-4-chlorokynurenine

• US 10,632,091 B2
• Filed: 05/14/2018
• Issued: 04/28/2020
• Est. Priority Date: 01/22/2013
• Status: Active Grant

• Current Assignee: VistaGen Therapeutics, Inc.
• Original Assignee: VistaGen Therapeutics, Inc.
• Inventors: Snodgrass, H. Ralph, Cato, Allen E., Hicklin, Jack S.
• Primary Examiner(s): Cruz, Kathrien A
• Application Number:
  US15/978,855
• Publication Number:
  US 20190125707A1
• Time in Patent Office: 715 Days
• Field of Search: 514564
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/198 Alpha-amino acids, e.g. alanine or edetic acid [EDTA] betaine A61K31/205; proline A61K31/401; tryptophan A61K31/405; histidine A61K31/4172; peptides not degraded to individual amino acids A61K38/00
• CPC Class Codes: A61K 9/0053 Mouth and digestive tract, i.e. intraoral and peroral administration rectal administration A61K9/0031
• CPC Class Codes: A61P 25/14 for treating abnormal movements, e.g. chorea, dyskinesia
• CPC Class Codes: A61P 25/16 Anti-Parkinson drugs
• CPC Class Codes: Y02A 50/30 Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

Compositions of L-4-chlorokynurenine are provided, as are methods for the treatment of neurologica dyslinction.

Claims

1. A method for ameliorating the side effect of dyskinesia induced by the administration of L-DOPA to a subject comprising the administration of a therapeutically effective amount of L-4-chlorokynurenine to the subject.

2. The method of claim 1 wherein the L-4-chlorokynurenine is administered as a pharmaceutical composition that per unit dose consists essentially of L-4-chlorokynurenine in an amount of about 50 to about 1,800 mg and a pharmaceutically acceptable ingredient.

3. The method of claim 2 wherein the L-4-chlorokynurenine is administered as a pharmaceutical composition that per unit dose consists essentially of L-4-chlorokynurenine in an amount of about 360 to about 1,440 mg.

4. The method of claim 3 wherein the pharmaceutical unit dose form is a tablet or a capsule.

5. The method of claim 3 wherein the pharmaceutical composition that per unit dose consists essentially of L-4-chlorokynurenine in an amount of about 360, 1,080 or 1,440 mg.

6. The method of claim 1, wherein the L-4-chlorokynurenine is orally administered.